AEGiS-14IAC: The impact of HAART in HIV+ hemophilic patients.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

The impact of HAART in HIV+ hemophilic patients.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10196)

Villafane Fioti MF
Argentine Hemophilic Foundation, Buenos Aires, Argentina

BACKGROUND: The response to highly active antiretroviral therapy (HAART) was evaluated in a group of hemophilic patients infected with HIV for more than 18 years.

METHODS: Twenty seven HIV+ hemophilc patients were included in this study. All had been infected prior to 1985 and received assistance at the Argentine Hemophilic Foundation. From june 1996, when subjects began HAART, until december 2001, the following parameters were evaluated: modification in CD4+ T cell counts, changes in viral load levels and mortality. Therapeutic success or failure was determined by clinical, virological and immunological parameters.

RESULTS: Nineteen (70,3%) patients received two nucleoside analogue reverse transcriptase inhibitors (NRTI) and one protease inhibitor (PI); six (22,2%) patients were treated with two NRTI and one non-nucleoside reverse transcriptase inhibitor (NNRTI); one (3,7%) received 2 NRTI plus 2 PI plus 1 NNRTI and another (3,7%) had 2 NRTI and 2 PI. The mean CD4+ T cell count when treatment started was 287 cell/ é L. After five years the mean CD4+ T cell count is 532 cell/ é L; 17 (40.7%) patients mantain CD4 + cell counts ≥500 cell/ é L, 15 (55,5%) have counts between 200-499 cell/ é L and one (3,7%) is below 200 cell/ é L. The mean viral load when treatment started was 53248 copies/mL. After 5 years of treatment, mean viral load is 1864 copies/mL. Sixteen (59,2%) patients have viral loads of ≤ 50 copies/mL; 2 (7,4%) between 50-500 copies/mL; six (22,2%) between 501-5000 copies/mL and 3 (11,1%) have ≥5000 copies/mL. No deaths occurred during the five year study period.

CONCLUSIONS: After five years of HAART treatment, 18 (66%) of the study patients mantain viral load ≤ 500 copies/mL, 26 (96,2%) have CD4+ T cell counts ≥ 200/ é L. The use of HAART is associated with a marked decrease in morbidity and mortality in the population studied.

Keywords: AEGIS, Antiretroviral Therapy, Highly Active, HIV, HIV Infections, CD4 Lymphocyte Count, Reverse Transcriptase Inhibitors, Viral Load, Anti-HIV Agents, HIV Protease Inhibitors, HIV Seropositivity, HIV-1 Reverse Transcriptase, T-Lymphocytes, HumanKWDaegis,antiretroviraltherapy,highlyactive,hiv,hivinfections,cd4lymphocytecount,reversetranscriptaseinhibitors,viralload,anti-hivagents,hivproteaseinhibitors,hivseropositivity,hiv-1reversetranscriptase,t-lymphocytes,human

020707
B10196

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.